• Citer

Clinically significant lower elvitegravir exposure during the third trimester of pregnant patients living with human immunodeficiency virus: Data from the pharmacokinetics of antiretroviral agents in hiv-infected pregnant women (PANNA) network

par Bukkems, Vera;Necsoi, Coca Valentina ;Tenorio, Carmen Hidalgo;Garcia, Coral;Rockstroh, Juergen;Schwarze-Zander, Caroline;Lambert, John Shearer;Burger, David;Konopnicki, Deborah ;Colbers, Angela P H
Référence Clinical infectious diseases, 71, 10, page (E714-E717)
Publication Publié, 2020-11

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

This phase 4 study investigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 women with human immunodeficiency virus type 1. The results support the recommendation against elvitegravir/cobicistat use during pregnancy, as the elvitegravir concentration at the end of the dosing interval (Ctrough) was reduced by 77%, with 85% of pregnant women having a Ctrough below the effective concentration (EC90).